Lenalidomida Stada

Lenalidomide, the active ingredient in Lenalidomida Stada, is an immunomodulatory agent (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomida Stada as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Lenalidomide is used in hematologic oncology to target malignant plasma cells and related disorders.

Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and may improve cytopenias. Mantle Cell Lymphoma: used in combination regimens to achieve disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness or lack of energy. - Diarrhea: loose stools that may be mild to moderate. - Rash: skin redness or itching. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: emergence of new cancers during therapy.

When prescribing Lenalidomida Stada, clinicians should observe several safety considerations. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombosis monitoring: assess risk factors and consider prophylactic anticoagulation. - Hematologic monitoring: regular complete blood counts to detect neutropenia or anemia. - Renal function: adjust use in patients with impaired kidney function. - Hepatic function: monitor liver enzymes during treatment. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Immunosuppressants: heightened risk of infection.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors: may increase plasma levels. - Vaccines: live attenuated vaccines should be avoided. - NSAIDs: may exacerbate renal toxicity.